Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Kopran Limited
KOPRANKopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India. Address: Parijat House, Mumbai, India, 400018
Analytics
Zielpreis von Wall Street
6 251.2 INRKGV
25.0041Dividendenrendite
1.34 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen KOPRAN
Dividenden-Analyse KOPRAN
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
29 %Verlauf der Dividende KOPRAN
Bewertung der Aktie KOPRAN
Finanzen KOPRAN
Ergebnisse | 2019 | Dynamik |